Edit
Cempra, Inc.
http://www.cempra.com/Last activity: 09.09.2014
Active - Reference to Melinta Therapeutics
Drug discovery and development company focused on infectious diseases and the treatment of drug-resistant bacteria
Location: United States, North Carolina, Chapel Hill
Total raised: $15M
Investors 2
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| 06.11.2022 | Hercules C... | htgc.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 09.09.2014 | - | $10M | - |
| 17.08.2011 | - | $5M | - |
Mentions in press and media 22
| Date | Title | Description |
| 09.09.2014 | Cempra, Inc. Receives $10 Million Milestone Payment From Toyama Chemical Co. Triggered by Solithromycin's Clinical Development Progress in Japan | Toyama Receives Regulatory Clearance to Begin Phase 2 Trial Following Completion of Successful Phase 1 Study in Japan CHAPEL HILL, N.C., Sept. 9, 2014 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP) today announced the receipt of a $10 milli... |
| 09.09.2014 | Cempra gets $10M milestone for its antibiotic development in Japan | Interestingly, antibiotic resistance is even more rampant a problem in Japan than in the U.S. with macrolide resistance in up to 78 percent of pneumococcus strains – so docs have limited oral therapeutic options, Fernandes said. It’s studyi... |
| 30.03.2012 | Antibiotics developer Cempra sees opportunity in prosthetic joint infections | “Every day has value,” Fernandes said in an interview with MedCity News. Cempra, which does not yet have any commercialized products, ended 2011 with a net loss of $25 million, up from $22.9 million in 2010, according to the company’s 2011 ... |
| 07.03.2012 | No IPO for immunotherapy company Argos Therapeutics | But the public markets have remained cool to life science IPOs. Merrimack Pharmaceuticals, a a Cambridge, Massachusetts firm developing cancer treatments, last month postponed its $80 million IPO. Chapel Hill, North Carolina-based Cempra Ph... |
| 03.02.2012 | Cempra IPO cuts targeted share price; pharma scales back phase 3 plans | Cempra has two clinical-stage drug candidates aimed at treating drug-resistant bacteria. CEM-101, also called solithromycin, has completed phase 2 clinical trials as a treatment for community-acquired bacterial pneumonia. The antibiotic tre... |
| 31.01.2012 | Cempra IPO expected this week; two other healthcare firms set to go public | Cempra’s two lead drug candidates are antibiotics that would address drug-resistant bacteria. Cempra is targeting an antibiotics market Datamonitor estimates was $19.6 billion in the United States, Japan and the five major European markets ... |
| 16.01.2012 | IPO for Cempra priced in $11 to $13 per share range; offering could raise $78M | Proceeds from the Cempra IPO will be used to finance clinical trials on Cempra’s drug candidates. CEM-101, also called solithromycin, is ready to start phase 3 clinical trials as a pneumonia treatment. The company also expects solithromycin... |
| 13.10.2011 | Cempra IPO to raise $86M for clinical trials on novel antibiotics | While the antibiotic market is a competitive space, Cempra said that the current slate of antibiotics doesn’t adequately fight all of the types of bacteria involved in a particular disease. The company adds that its compounds can address th... |
| 15.09.2011 | Cempra antibiotic compound as effective, safer than levofloxacin | But levofloxacin carries safety and toxicity risks. The drug can increase chances a patient will develop tendinitis or suffer a ruptured tendon, a risk that increases with age of a patient. The drug can also exacerbate muscle weakness in pe... |
| 17.08.2011 | Antibacterials pharma Cempra raises $5M; lead compound targets MRSA | A Cempra spokesman said the company cannot discuss the financing right now. But CEO Prabhavathi Fernandes has said the company is looking to partner with a large pharmaceutical company who could take TAKSTA through phase 3 clinical trials. ... |
Show more